LexaGene Closes Multiple MiQLab Sales
BEVERLY, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce two purchase orders from Kuma Veterinary Clinic and the Emergency Veterinary Services of Roanoke.
Dr. Jack Regan, LexaGene’s Founder and CEO commented, “I’m pleased to announce that we have closed additional MiQLab System sales to private hospitals. Veterinarians are learning more about our system and recognizing how wrong it is to have to wait days to weeks for a reference lab to provide infectious disease results that can impact the well-being of their patients. Our MiQLab System provides them a solution to this problem, as it delivers high-quality results at the point of need in just ~2 hours. This time savings empowers them to make evidence-based decisions to improve the quality of the care they provide.”
Gwyneth Shugart, CVT and co-owner of Kuma Veterinary Clinic commented, “We purchased the MiQLab system to offer better services to our clients and the pets they love. Too often, slow diagnostics have prevented us from more rapidly improving our patients’ health, which has led to frustration, unnecessary pain and suffering, and higher costs. It is truly exciting to have this new diagnostic in our hospital, as we put the days of practicing medicine based on empiric diagnosis behind us.”
Julie Griggs, CVT, LexaGene’s Global Director of Sales stated, “The vast majority of specialty and 24-hour emergency veterinary hospitals are no longer pivate and are consolidated or owned by large corporations. Over the last two months we’ve made good progress in the sales cycle for large corporations, where we target multi-unit sales. We expect the corporate sales will start a wave of adoption across the industry as veterinary practices will not want to be left behind and will seek to modernize their technology to keep up with the expectations of their clients and new industry standards.”
On Behalf of the Board of Directors
About LexaGene Holdings Inc.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Corporate & Media Contact: Gail Winslow Director, Marketing [email protected] 978.482.6237 Investors: [email protected] 800.215.1824
Session Details TBA
Keynote Presentation - Open to all Badge Holders
The Need for Speed: How Fast can 6G Transmit?